$KLTO
Stock $klto

$klto Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000121390024033573 Filed on April 17, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$395.6K	$324.9K	$1.301M
YoY Change	10.52%	35.64%	97.99%
% of Gross Profit
Research & Development	$0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$395.6K	$324.9K	$1.301M
YoY Change	10.52%	35.64%	97.99%
Operating Profit	-$395.6K		-$1.301M
YoY Change	10.52%		97.99%
Interest Expense	-$15.06K	$509.9K	$3.364M
YoY Change	-103.77%	-54.43%	113.25%
% of Operating Profit
Other Income/Expense, Net	-$56.03K	$15.90K	-$26.50K
YoY Change	164.3%		-104.77%
Pretax Income	-$451.6K	$200.9K	$2.037M
YoY Change	-2313.92%	-77.15%	37.95%
Income Tax		$112.0K	$690.6K
% Of Pretax Income		55.75%	33.91%
Net Earnings	-$451.6K	$88.92K	$1.346M
YoY Change	194.14%	-87.58%	9.14%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03
Diluted Earnings Per Share	-$0.03	$0.01	$0.14
COMMON SHARES
Basic Shares Outstanding	1.760M shares	8.802M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$845.3K	$172.5K	$172.5K
YoY Change	583.27%	-49.4%	-49.4%
Cash & Equivalents	$845.3K	$172.5K
Short-Term Investments
Other Short-Term Assets	$154.5K	$27.00K	$27.00K
YoY Change	14.28%	-72.78%	-72.78%
Inventory
Prepaid Expenses	$154.5K	$27.00K
Receivables
Other Receivables
Total Short-Term Assets	$999.8K	$199.5K	$199.5K
YoY Change	286.16%	-54.67%	-54.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$19.26M	$19.26M
YoY Change		-83.65%	-83.65%
Other Assets	$2.310M	$2.186M
YoY Change
Total Long-Term Assets	$2.310M	$19.26M	$19.26M
YoY Change	-95.94%	-83.65%	-83.65%
TOTAL ASSETS
Total Short-Term Assets	$999.8K	$199.5K	$199.5K
Total Long-Term Assets	$2.310M	$19.26M	$19.26M
Total Assets	$3.309M	$19.46M	$19.46M
YoY Change	-94.22%	-83.55%	-83.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$33.99K	$151.3K
YoY Change
Accrued Expenses	$250.4K	$1.497M	$1.497M
YoY Change	-8.45%	966.13%	468.65%
Deferred Revenue
YoY Change
Short-Term Debt	$15.06K	$65.00K	$65.00K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$898.6K	$2.313M	$2.313M
YoY Change	-33.52%	356.91%	356.91%
LONG-TERM LIABILITIES
Long-Term Debt	$3.900M	$1.540M	$1.540M
YoY Change	348.28%
Other Long-Term Liabilities	$62.22K	$4.371M	$4.371M
YoY Change	-98.58%	0.61%	0.61%
Total Long-Term Liabilities	$3.962M	$5.911M	$5.911M
YoY Change	-24.47%	36.06%	36.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$898.6K	$2.313M	$2.313M
Total Long-Term Liabilities	$3.962M	$5.911M	$5.911M
Total Liabilities	$4.861M	$8.242M	$8.242M
YoY Change	-27.73%	67.19%	67.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.536M	-$7.351M
YoY Change	-8.43%	81.73%
Common Stock	$3.680M	$340.00
YoY Change	1082327.35%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.551M	$11.21M	$11.21M
YoY Change
Total Liabilities & Shareholders Equity	$3.309M	$19.46M	$19.46M
YoY Change	-94.22%	-83.55%	-83.55%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$451.6K	$88.92K	$1.346M
YoY Change	194.14%	-87.58%	9.14%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$552.9K	-$248.8K	-$1.263M
YoY Change	7.67%	239.98%	156.1%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$53.50K	$39.07M	$101.9M
YoY Change	-100.08%		-187.74%
Cash From Investing Activities	-$53.50K	$39.07M	$101.9M
YoY Change	-100.08%		-187.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.613M	-38.79M	-100.8M
YoY Change	-102.57%		-186.19%
NET CHANGE
Cash From Operating Activities	-552.9K	-248.8K	-1.263M
Cash From Investing Activities	-53.50K	39.07M	101.9M
Cash From Financing Activities	1.613M	-38.79M	-100.8M
Net Change In Cash	1.007M	26.20K	-168.4K
YoY Change	17443.73%	-135.8%	-150.13%
FREE CASH FLOW
Cash From Operating Activities	-$552.9K	-$248.8K	-$1.263M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41340
CY2023	dei	Entity Registrant Name EntityRegistrantName	REDWOODS ACQUISITION CORP.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2727441
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	61037	usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-78955	usd
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1115 Broadway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	12th Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10010
CY2023	dei	City Area Code CityAreaCode	(646)
CY2023	dei	Local Phone Number LocalPhoneNumber	916-5315
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	56560000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1760194	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	East Hanover, NJ
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	172535	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	340962	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	26995	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	99196	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	199530	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	440158	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	19256423	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	117806478	usd
CY2023Q4	us-gaap	Assets Assets	19455953	usd
CY2022Q4	us-gaap	Assets Assets	118246636	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	396669	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	140370	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	65000	usd
CY2023Q4	rwod	Franchise Tax Payable Current FranchiseTaxPayableCurrent	75600	usd
CY2022Q4	rwod	Franchise Tax Payable Current FranchiseTaxPayableCurrent	122801	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	751562	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	243070	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	1024249	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2313080	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	506241	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	58300	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	31800	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	17919	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	78955	usd
CY2023Q4	rwod	Deferred Underwriting Fee Payables DeferredUnderwritingFeePayables	4312500	usd
CY2022Q4	rwod	Deferred Underwriting Fee Payables DeferredUnderwritingFeePayables	4312500	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8241799	usd
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	1760194	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	11500000	shares
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.55
CY2022Q4	us-gaap	Liabilities Liabilities	4929496	usd
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.21
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	18564656	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	117361652	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3405000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3405000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	340	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	340	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7350842	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4044852	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7350502	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4044512	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19455953	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118246636	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1225241	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	533992	usd
CY2023	rwod	Franchise Tax Expenses FranchiseTaxExpenses	75600	usd
CY2022	rwod	Franchise Tax Expenses FranchiseTaxExpenses	123026	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1300841	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-657018	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3364038	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1656478	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	26500	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-555917	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2036697	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1555377	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	690572	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	322025	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1346125	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	1233352	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4044512	usd
CY2023	rwod	Stock Issued During Period Value Exercise Tax Liability StockIssuedDuringPeriodValueExerciseTaxLiability	-1024249	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	3627865	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1346125	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7350502	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3559	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	115000000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	5300000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	100	usd
CY2022	rwod	Stock Issued During Period Value Underwriter Commissions StockIssuedDuringPeriodValueUnderwriterCommissions	-7187500	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-462536	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	587717	usd
CY2022	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	94875000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	6901405	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	29388057	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	1233352	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4044512	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1346125	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	1233352	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	3364038	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1656478	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	26500	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-555917	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-72201	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	99196	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	256299	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	140370	usd
CY2023	rwod	Increase Decrease In Franchise Tax Payable IncreaseDecreaseInFranchiseTaxPayable	-47201	usd
CY2022	rwod	Increase Decrease In Franchise Tax Payable IncreaseDecreaseInFranchiseTaxPayable	122801	usd
CY2023	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	508492	usd
CY2022	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	243070	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1262659	usd
CY2023Q4	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	39255410	usd
CY2023Q4	rwod	Redemption Value Per Share RedemptionValuePerShare	10.79
CY2023Q4	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	35000	usd
CY2023Q4	us-gaap	Deposits Deposits	35000	usd
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.1
CY2023	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1	pure
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	60000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-493043	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	116150000	usd
CY2023	us-gaap	Proceeds From Sale Of Insurance Investments ProceedsFromSaleOfInsuranceInvestments	519232	usd
CY2023	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	102424861	usd
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1030000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	101914093	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-116150000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	115000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5300000	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	100	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1540000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	200000	usd
CY2023	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	65000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	102424861	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	200000	usd
CY2022	rwod	Repayment Of Advance From Related Party RepaymentOfAdvanceFromRelatedParty	8511	usd
CY2022	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement	2875000	usd
CY2022	rwod	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	462537	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-100819861	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116979052	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-168427	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	336010	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	340962	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4952	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	172535	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	340962	usd
CY2022	rwod	Initial Classification Of Common Stock Subject To Redemption InitialClassificationOfCommonStockSubjectToRedemption	94873850	usd
CY2022	rwod	Initial Recognition Of Warrant Liabilities InitialRecognitionOfWarrantLiabilities	587717	usd
CY2022	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	4312500	usd
CY2022	rwod	Allocation Of Offering Costs To Common Stock Subject To Redemption AllocationOfOfferingCostsToCommonStockSubjectToRedemption	6901405	usd
CY2023	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	3627865	usd
CY2022	rwod	Net Loss Including Accretion Of Common Stock To Redemption Value NetLossIncludingAccretionOfCommonStockToRedemptionValue	29388057	usd
CY2023	rwod	Exercise Taxliability ExerciseTaxliability	1024250	usd
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q2	rwod	Total Gross Proceeds TotalGrossProceeds	4775000	usd
CY2023	rwod	Units Issued During Period Shares New Issues UnitsIssuedDuringPeriodSharesNewIssues	1500000	shares
CY2022Q2	rwod	Purchased Public Units PurchasedPublicUnits	1500000	shares
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q2	rwod	Total Gross Proceeds TotalGrossProceeds	525000	usd
CY2023Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	8365339	usd
CY2023	rwod	Underwriting Fees UnderwritingFees	2875000	usd
CY2023	rwod	Deferred Underwriting Fees DeferredUnderwritingFees	4312500	usd
CY2023	rwod	Other Offering Costs OtherOfferingCosts	1177839	usd
CY2022Q2	rwod	Total Amount TotalAmount	116150000	usd
CY2023	rwod	Aggregate Of Shares AggregateOfShares	6103350	shares
CY2023	rwod	Redemption Value RedemptionValue	63169451	usd
CY2023Q4	rwod	Redemption Per Share RedemptionPerShare	10.35
CY2023	rwod	Initial Threemonth Extension InitialThreemonthExtension	360000	usd
CY2023	rwod	Onemonth Extension OnemonthExtension	120000	usd
CY2023Q4	rwod	Trust Account Amount TrustAccountAmount	120000	usd
CY2023Q4	rwod	Trust Account Amount TrustAccountAmount	35000	usd
CY2023Q4	rwod	Aggregate Shares AggregateShares	3636456	shares
CY2023	rwod	Description Of Contingent Consideration Shares DescriptionOfContingentConsiderationShares	(i) 2,000,000 Contingent Consideration Shares upon the Company achieving a closing price equal to or exceeding $12.50 for 10 trading days within a 20-day trading period in the first three years following the closing of the Merger; (ii) 2,000,000 Contingent Consideration Shares upon the Company achieving a closing price equal to or exceeding $15.00 for 10 trading days within a 20-day trading period in the first three years following the closing of the Merger; and (iii) 1,000,000 Contingent Consideration Shares upon the Company achieving a closing price equal to or exceeding $20.00 for 10 trading days within a 20-day trading period in the first five years following the closing of the Merger
CY2023	rwod	Description Of Deferred Shares DescriptionOfDeferredShares	The underwriters have agreed to waive their rights to their deferred underwriting commissions (see Note 7) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares.
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.1
CY2023	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2875000	shares
CY2023Q2	rwod	Termination Date TerminationDate	2024-06-04
CY2023Q2	us-gaap	Interest Income Other InterestIncomeOther	519231	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	153089	usd
CY2023Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	150000	usd
CY2023Q4	us-gaap	Cash Cash	172535	usd
CY2023Q4	rwod	Working Capital Deficit WorkingCapitalDeficit	2113550	usd
CY2023Q1	rwod	Sponsor Provided Loan SponsorProvidedLoan	150000	usd
CY2023Q1	rwod	Sponsor Provided Loan SponsorProvidedLoan	360000	usd
CY2023Q2	rwod	Sponsor Provided Loan SponsorProvidedLoan	360000	usd
CY2023Q3	rwod	Sponsor Provided Loan SponsorProvidedLoan	150000	usd
CY2023Q3	rwod	Sponsor Provided Loan SponsorProvidedLoan	120000	usd
CY2023Q4	rwod	Sponsor Provided Loan SponsorProvidedLoan	400000	usd
CY2023Q4	us-gaap	Deposits Deposits	35000	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01	pure
CY2022Q3	us-gaap	Reporting Unit Percentage Of Fair Value In Excess Of Carrying Amount ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount	0.01	pure
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1024250	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these consolidated financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	172535	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	340962	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	8365339	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1346125	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1233352	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	3627864	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	29388057	usd
CY2023	rwod	Net Loss Including Accretion Of Common Stock Redemption Value NetLossIncludingAccretionOfCommonStockRedemptionValue	2281739	usd
CY2022	rwod	Net Loss Including Accretion Of Common Stock Redemption Value NetLossIncludingAccretionOfCommonStockRedemptionValue	28154705	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution and money market funds held in the Trust Account. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	19256423	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	117806478	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	19256423	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	117806478	usd
CY2023Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	1500000	usd
CY2023Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2023	us-gaap	Partners Capital Account Units Sold In Public Offering PartnersCapitalAccountUnitsSoldInPublicOffering	11500000	shares
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	115000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	10695000	usd
CY2022Q4	rwod	Proceeds Allocated To Public Rights ProceedsAllocatedToPublicRights	-9430000	usd
CY2022Q4	rwod	Offering Costs Of Public Shares OfferingCostsOfPublicShares	-6901405	usd
CY2022	rwod	Accretion Of Class A Ordinary Shares To Accreted Value AccretionOfClassAOrdinarySharesToAccretedValue	29388057	usd
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	117361652	usd
CY2023	rwod	Accretion Of Class A Ordinary Shares To Accreted Value AccretionOfClassAOrdinarySharesToAccretedValue	3627865	usd
CY2023	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	102424861	usd
CY2023Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	18564656	usd
CY2023	rwod	Aggregate Private Units AggregatePrivateUnits	477500	shares
CY2023Q4	rwod	Sale Of Stock Price Per Shares SaleOfStockPricePerShares	10
CY2023	rwod	Aggregate Purchase Price AggregatePurchasePrice	4775000	usd
CY2023	rwod	Additional Aggregates Private Units AdditionalAggregatesPrivateUnits	52500	shares
CY2023	us-gaap	Sale Leaseback Transaction Gross Proceeds Financing Activities SaleLeasebackTransactionGrossProceedsFinancingActivities	525000	usd
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	150000	usd
CY2023Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	360000	usd
CY2023Q3	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	150000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1540000	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd
CY2023	rwod	Accrued Expenses AccruedExpenses	120000	usd
CY2022	rwod	Accrued Expenses AccruedExpenses	90000	usd
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred	210000	usd
CY2022	us-gaap	Interest Costs Incurred InterestCostsIncurred	90000	usd
CY2023	rwod	Underwriting Discount Percentage UnderwritingDiscountPercentage	0.025	pure
CY2023	rwod	Generating Gross Proceeds GeneratingGrossProceeds	2875000	usd
CY2023	rwod	Deferred Fee DeferredFee	0.0375	pure
CY2023Q4	us-gaap	Purchase Options Land PurchaseOptionsLand	100	usd
CY2023	rwod	Unit Purchase Option UnitPurchaseOption	345000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.5
CY2023	rwod	Aggregate Exercise Price AggregateExercisePrice	3967500	usd
CY2023	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P5Y
CY2023	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	100	usd
CY2023	rwod	Right Of First Refusal Description RightOfFirstRefusalDescription	The Company has granted Chardan a right of first refusal, for a period of 18 months after the date of the consummation of a Business Combination, to act as a book-running manager or placement agent, with at least 30% of the economics, for any and all future public and private equity, equity linked and debt offerings of the Company or any of its successors or subsidiaries.
CY2023	us-gaap	Debtor Reorganization Items Legal And Advisory Professional Fees DebtorReorganizationItemsLegalAndAdvisoryProfessionalFees	200000	usd
CY2023	us-gaap	Legal Fees LegalFees	500000	usd
CY2023	rwod	Deferred Legal Fees Service DeferredLegalFeesService	1.2	shares
CY2022	rwod	Deferred Legal Fees Service DeferredLegalFeesService	0.3	shares
CY2023	rwod	Market Price Percentage MarketPricePercentage	1.15	pure
CY2023Q4	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	16.5
CY2023	rwod	Market Valuein Percentage MarketValueinPercentage	1.65	pure
CY2023Q4	rwod	Price Per Warrant PricePerWarrant	0.01
CY2023	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	16.5
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	322025	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	17919	usd
CY2023Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	58300	usd
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	31800	usd
CY2022Q4	rwod	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisAssetValue	31800	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Purchases FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchases	26500	usd
CY2023Q4	rwod	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisAssetValue	58300	usd
CY2022Q2	rwod	Fair Value Of Private Warrants FairValueOfPrivateWarrants	587717	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2023Q4	rwod	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Underlying Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsUnderlyingSharePrice	10.7
CY2022Q4	rwod	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Underlying Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsUnderlyingSharePrice	10.06
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0351	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0297	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0384	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0399	pure
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	308260	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	112138	usd
CY2023Q4	rwod	Unrealized Gain On Investment Held In Trust Account UnrealizedGainOnInvestmentHeldInTrustAccount	17919	usd
CY2022Q4	rwod	Unrealized Gain On Investment Held In Trust Account UnrealizedGainOnInvestmentHeldInTrustAccount	78955	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	290341	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	33183	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	308260	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	112138	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	17919	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	78955	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	751609	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	243070	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-257159	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-33183	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	196122	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	112138	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	690572	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	322025	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0027	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0751	pure
CY2023	rwod	Transaction Costs TransactionCosts	0.03	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0963	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0721	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.339	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.207	pure
CY2023Q4	us-gaap	Deferred Taxes Business Combination Valuation Allowance Available To Reduce Intangible Assets DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIntangibleAssets	308260	usd
CY2022Q4	us-gaap	Deferred Taxes Business Combination Valuation Allowance Available To Reduce Intangible Assets DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIntangibleAssets	112138	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	690572	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	78955	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent		usd
CY2022	us-gaap	Proceeds From Sale Of Insurance Investments ProceedsFromSaleOfInsuranceInvestments		usd
CY2022	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects		usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2022	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	rwod	Repayment Of Advance From Related Party RepaymentOfAdvanceFromRelatedParty		usd
CY2023	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement		usd
CY2023	rwod	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts		usd
CY2023	rwod	Initial Classification Of Common Stock Subject To Redemption InitialClassificationOfCommonStockSubjectToRedemption		usd
CY2023	rwod	Initial Recognition Of Warrant Liabilities InitialRecognitionOfWarrantLiabilities		usd
CY2023	us-gaap	Other Underwriting Expense OtherUnderwritingExpense		usd
CY2023	rwod	Allocation Of Offering Costs To Common Stock Subject To Redemption AllocationOfOfferingCostsToCommonStockSubjectToRedemption		usd
CY2022	rwod	Exercise Taxliability ExerciseTaxliability		usd
CY2023Q4	us-gaap	Long Term Debt Term LongTermDebtTerm	P5Y
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards		usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	rwod	Transaction Costs TransactionCosts		pure
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001907223

Files In Submission

Name	View Source	Status
0001213900-24-033573-index-headers.html	Edgar Link	pending
0001213900-24-033573-index.html	Edgar Link	pending
0001213900-24-033573.txt	Edgar Link	pending
0001213900-24-033573-xbrl.zip	Edgar Link	pending
ea0202986-10k_redwoods.htm	Edgar Link	pending
ea020298601ex10-18_redwoods.htm	Edgar Link	pending
ea020298601ex21_redwoods.htm	Edgar Link	pending
ea020298601ex31-1_redwoods.htm	Edgar Link	pending
ea020298601ex31-2_redwoods.htm	Edgar Link	pending
ea020298601ex32-1_redwoods.htm	Edgar Link	pending
ea020298601ex32-2_redwoods.htm	Edgar Link	pending
ea020298601ex97-1_redwoods.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
ea0202986-10k_redwoods_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rwod-20231231.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rwod-20231231_def.xml	Edgar Link	unprocessable
rwod-20231231_lab.xml	Edgar Link	unprocessable
rwod-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
rwod-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KLTO
Stock $klto

2024 Q2 Form 10-K Financial Statement

#000121390024033573 Filed on April 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KLTO Stock $klto

2024 Q2 Form 10-K Financial Statement

#000121390024033573 Filed on April 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KLTO
Stock $klto